Covetrus
Market Cap
US$1.5b
Last Updated
2019/09/18 00:39 UTC
Data Sources
Company Financials +
Executive Summary
Covetrus, Inc. operates as an animal-health technology and services company.
Snowflake
Fundamentals
Good value with moderate growth potential.
Risks
- Covetrus has significant price volatility in the past 3 months.
Similar Companies
Share Price & News
How has Covetrus's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
-11.3%
NasdaqGS:CVET
0.1%
US Healthcare
0.8%
US Market
1 Year Return
n/a
NasdaqGS:CVET
-8.4%
US Healthcare
1.9%
US Market
No trading data on CVET.
No trading data on CVET.
Share holder returns
| CVET | Industry | Market | |
|---|---|---|---|
| 7 Day | -11.3% | 0.1% | 0.8% |
| 30 Day | -11.6% | -1.4% | 3.4% |
| 90 Day | -46.3% | -0.7% | 2.1% |
| 1 Year | n/a | -7.0%-8.4% | 4.2%1.9% |
| 3 Year | n/a | 30.6%25.3% | 46.7%37.2% |
| 5 Year | n/a | 64.9%55.1% | 62.3%44.5% |
Price Volatility Vs. Market
How volatile is Covetrus's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall St
How Does Covetrus's (NASDAQ:CVET) P/E Compare To Its Industry, After The Share Price Drop?1 month ago | Simply Wall St
These 4 Measures Indicate That Covetrus (NASDAQ:CVET) Is Using Debt ExtensivelyValuation
Is Covetrus undervalued based on future cash flows and its price relative to the stock market?
>50%
Discount to future cash flow value
Intrinsic Value Based on Future Cash Flows
Covetrus's share price is below the future cash flow value, and at a moderate discount (> 20%).
Covetrus's share price is below the future cash flow value, and at a substantial discount (> 40%).
Price Based on Earnings
Covetrus is overvalued based on earnings compared to the US Healthcare industry average.
Covetrus is overvalued based on earnings compared to the United States of America market.
Price Based on Expected Growth
Covetrus is good value based on expected growth next year.
Price Based on Value of Assets
Covetrus is good value based on assets compared to the US Healthcare industry average.
Next Steps
Future Growth
How is Covetrus expected to perform in the next 1 to 3 years based on estimates from 7 analysts?
76.2%
Forecasted annual earnings growth
Earnings and Revenue Growth Estimates
Future Annual Growth Analysis
Covetrus's revenue is expected to grow by 5.6% yearly, however this is not considered high growth (20% yearly).
Covetrus's earnings are expected to grow significantly at over 20% yearly.
Covetrus's revenue growth is positive but not above the United States of America market average.
Covetrus's earnings growth is expected to exceed the United States of America market average.
Covetrus's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Earnings per Share Growth Estimates
Future Return on Equity
Covetrus is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
Next Steps
Past Performance
How has Covetrus performed over the past 5 years?
-1.9%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Covetrus's year on year earnings growth rate was negative over the past 5 years and the most recent earnings are below average.
Covetrus's 1-year earnings growth is negative, it can't be compared to the 5-year average.
Covetrus's 1-year earnings growth is negative, it can't be compared to the US Healthcare industry average.
Return on Equity
Covetrus has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
Return on Assets
Covetrus used its assets less efficiently than the US Healthcare industry average last year based on Return on Assets.
Return on Capital Employed
Unable to establish if Covetrus improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to insufficient past data.
Next Steps
Financial Health
How is Covetrus's financial position?
Financial Position Analysis
Covetrus is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Covetrus's long term commitments exceed its cash and other short term assets.
Debt to Equity History and Analysis
Covetrus's level of debt (52.4%) compared to net worth is high (greater than 40%).
Unable to establish if Covetrus's debt level has increased without past 5-year debt data.
Debt is not well covered by operating cash flow (9.5%, less than 20% of total debt).
Interest payments on debt are not well covered by earnings (EBIT is 2.5x annual interest expense, ideally 3x coverage).
Balance Sheet
Low level of unsold assets.
Debt is covered by short term assets, assets are 1x debt.
Next Steps
Dividend
What is Covetrus's current dividend yield, its reliability and sustainability?
13.60%
Expected Dividend Yield
Dividend Yield and Payments Analysis
Unable to evaluate Covetrus's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Covetrus's dividend against the top 25% market benchmark as the company has not reported any payouts.
Unable to perform a dividend volatility check as Covetrus has not reported any payouts.
Unable to verify if Covetrus's dividend has been increasing as the company has not reported any payouts.
Current Payout to Shareholders
Unable to calculate sustainability of dividends as Covetrus has not reported any payouts.
Future Payout to Shareholders
Analysts do not expect the company to pay a dividend in 3 years, no need to check if it is sustainable.
Next Steps
Management
What is the CEO of Covetrus's salary, the management and board of directors tenure and is there insider trading?
0.6yrs
Average management tenure
CEO
Ben Shaw (40yo)
0.6yrs
Tenure
Mr. Benjamin J. Shaw, also known as Ben, has been President, Chief Executive Officer and Director of Covetrus, Inc. since February 2019. Mr. Shaw co-founded Black Point Group and served as Founding Partner ...
Management Age and Tenure
0.6yrs
Average Tenure
51.5yo
Average Age
The average tenure for the Covetrus management team is less than 2 years, this suggests a new team.
Board Age and Tenure
0.6yrs
Average Tenure
61yo
Average Age
The average tenure for the Covetrus board of directors is less than 3 years, this suggests a new board.
Insider Trading
More shares have been bought than sold by Covetrus individual insiders in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Chief Legal Officer Senior VP |
| Shares | 1,684 |
| Max Price | US$14.90 |
| Entity | Individual |
| Role | Chief Financial Officer EVP & CFO |
| Shares | 5,060 |
| Max Price | US$14.80 |
| Entity | Individual |
| Role | Chief Executive Officer President |
| Shares | 1,800 |
| Max Price | US$13.87 |
| Entity | Individual |
| Role | Senior Key Executive Senior VP & President of Global Software Services |
| Shares | 685 |
| Max Price | US$28.33 |
| Entity | Individual |
| Shares | 70,000 |
| Max Price | US$28.03 |
Ownership Breakdown
Management Team
Anthony Providenti (52yo)
Senior Vice President of Corporate Development
- Tenure: 0.6yrs
Christine Komola (51yo)
EVP & CFO
- Tenure: 0.6yrs
Ben Shaw (40yo)
President
- Tenure: 0.6yrs
Nick Jansen
Vice President of Investor Relations
- Tenure: 0yrs
Russell Cooke (53yo)
Senior VP & Operational CFO
- Tenure: 0.6yrs
Erin Brennan (48yo)
Senior VP
- Tenure: 0.6yrs
David Dollar (53yo)
Senior VP & President of Global Software Services
- Tenure: 0.6yrs
Michael Ellis (59yo)
Senior VP & President of Europe
- Tenure: 0.6yrs
Kiní Schoop
Director of Public Relations
- Tenure: 0yrs
Laura Phillips (49yo)
VP, Chief Accounting Officer & Principal Accounting Officer
- Tenure: 0.3yrs
Board Members
Deborah Ellinger (60yo)
Director
- Tenure: 0.6yrs
Phil Laskawy (78yo)
Lead Independent Director
- Tenure: 0.6yrs
Sandra Helton (69yo)
Director
- Tenure: 0.6yrs
Steven Paladino (62yo)
Director
- Tenure: 1.4yrs
Mark Manoff (62yo)
Director
- Tenure: 0.6yrs
Ravi Sachdev (42yo)
Director
- Tenure: 0.6yrs
Ben Wolin (43yo)
Chair of Board of Directors
- Tenure: 0yrs
Ted McNamara (54yo)
Director
- Tenure: 0.6yrs
David Shaw (68yo)
Director
- Tenure: 0.6yrs
Ben Shaw (40yo)
President
- Tenure: 0.6yrs
Company Information
Covetrus, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Covetrus, Inc.
- Ticker: CVET
- Exchange: NasdaqGS
- Founded:
- Industry: Health Care Distributors
- Sector: Healthcare
- Market Cap: US$1.487b
- Shares outstanding: 111.98m
- Website: https://www.covetrus.com
Number of Employees
Location
- Covetrus, Inc.
- 7 Custom House Street
- Portland
- Maine
- 4101
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| CVET | NasdaqGS (Nasdaq Global Select) | Yes | Share Capital | US | USD | Feb 2019 |
| 2NJ | DB (Deutsche Boerse AG) | Yes | Share Capital | DE | EUR | Feb 2019 |
Biography
Covetrus, Inc. operates as an animal-health technology and services company. It operates through two segments, Supply Chain, and Technology and Value-Added Services. The company sells and distributes pharm ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/09/18 00:39 |
| End of Day Share Price | 2019/09/17 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/29 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.